Coordinator: Angélique Gougelet, PhD
Born on March 13th, 1980 at Châtenay-Malabry, France
Centre de Recherche des Cordeliers-Umrs1138
Team "Oncogenic functions of beta-catenin signaling in the liver"
15 rue de l'école de médecine
75006 Paris
01 44 27 60 36
angelique.gougelet@inserm.fr

ACTUAL POSITION

"Chargé de Recherche Classe Normale" since october 2015

EDUCATION

10/2010-10/2015: Post-doctoral Fellow, INSERM U1016, Institut Cochin, Paris, France
05/2007-07/2010: Post-doctoral Fellow, INSERM U590, Centre Léon Bérard, Lyon, France
01/2004-01/2007: PhD in Biology, Paris XI University, Châtenay-Malabry, France

TRAINING & TEACHING

- Internships of 17 students, 1 PhD student
- Teaching in L3 Pro « Microbiologie Industrielle et Biotechnologies » (2011-now) and M1 "Magistère Européen de Génétique" (2019-now), Université de Paris
- Organizer of workshops for the "Fête de la Science" (2016-2018, 2021) and for young students (2016-now)

SCIENTIFIC EXPERTISE

- Editorial member of the "World Journal of Hepatology" Journal since April 2018
- Reviewing of more than 100 international manuscripts (Gut, Liver International, Journal of Hepatology, Hepatology, International Journal of Hepatology…)
- Expert for a grant for AFEF, National Science Centre Poland, la Ligue Nationale contre le Cancer, Telethon Grant in Italy and a grant for the Israel Science Foundation
- Reporter of four theses, five CST
- Reporter for a « Maitre de Conférences » recruitment examination
- Member of the selection committee for abstracts during AFEF meeting 2020
- Member of the organizing committee for seminars in Centre de Recherche des Cordeliers
- Representative of the "Chargé de Recherche" in Cochin Institute
- Speaker in 20 meetings, invited in 6

FUNDINGS

- ANR Jeune Chercheur DLK1-EPILIV 2018-2021
- AAP *Association Française d'Etude du Foie* 2018

PRIZE AND DISTINCTIONS

- APEMM Prize for the best manuscript in 2015
- Young investigator Bursaries in EASL 2013 and EASL HCC summit 2014
- Young researcher Bursaries in AFEF 2013
- Prize of the best talk in the Wnt meeting 2010

PUBLICATIONS

15 international manuscripts, 11 international reviews, 2 book chapters



International manuscripts

M. Cadoux, S. Caruso, S. Pham, **A. Gougelet**, … and J-P. Couty. NKG2D ligands expression is down regulated by beta-catenin signalling and correlates with HCC aggressiveness in mice and human. **J.Hepatol**. 2021 Jan 20:S0168-8278(21)00028-3. doi: 10.1016/j.jhep.2021.01.017.

R. Riou, M. Ladli, S.Gerbal-Chaloin, P. Bossard, **A. Gougelet**… and S. Colnot. ARID1A loss in adult hepatocytes unleashes β-catenin-mediated erythropoietin transcription. **eLife**. 2020 Oct 21;9:e53550. doi: 10.7554/eLife.53550.

A. Gougelet*, C. Sartor*, N. Senni*, … and S.Colnot. Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography **Gastroenterology.** 2019; 157 (3): 807-822. doi: 10.1053/j.gastro.2019.05.069.

C. Sartor, …, **A. Gougelet*** and S. Colnot*. The concomitant loss of APC and HNF4α in adult hepatocytes does not contribute to hepatocarcinogenesis driven by β-catenin activation. ***Liver Int.*** 2019; 39 (4): 727-739. doi: 10.1111/liv.14068* AG and SC contributed equally to this work

Senni N, Savall M, Cabrerizo Granados D, Alves-Guerra MC, Sartor C, Lagoutte I, **Gougelet A**, Terris B, Gilgenkrantz H, Perret C, Colnot S, Bossard P. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids. **Gut.** 2018; 68 (2): 322-334. doi: 10.1136/gutjnl-2017-315448.

A. Gougelet, C. Sartor, L. Bachelot, *et al.* Antitumor activity of an inhibitor of miR-34a in liver cancer mutated for β-catenin. ***Gut.*** 2016; 65:6 1024-1034. doi: 10.1136/gutjnl-2014-308969.

A. Gougelet, C.Torre, P.Veber, *et al.* T-cell factor 4 and β-catenin chromatin occupancies pattern zonal liver metabolism. ***Hepatology.*** 2014 Jun; 59(6): 2344-57. doi: 10.1002/hep.26924.

Anson M, Crain-Denoyelle AM, Baud V, Chereau F, **Gougelet A**, *et al.* Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. **J Clin Invest.** 2012 Feb 1; 122(2): 586-99. doi: 10.1172/JCI43937.

Gougelet A, Perez J, Pissaloux D, *et al.* miRNA profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas. **Sarcoma.** 2011; 2011:460650.

Gougelet A, Pissaloux D, Besse A, *et al.* Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. **Int J Cancer.** 2011 Aug 1; 129(3): 680-90.

Gougelet A, Mansuy A, Blay JY, *et al.* Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody**. PLoS One**. 2009 Nov 30; 4(11): e8026.

Gougelet A., Mueller S. O., Korach K. S. and Renoir J-M. Œstrogen receptor (ER) pathways to Œstrogen response elements: the transactivation function AF-1 acts as the keystone of ER-mediated transcription repression of ER. **J. Steroid Biochem Mol Biol**, 2007. 104(3-5): 110-22.

Gougelet A., Bouclier C., Marsaud V., *et al.* Estrogen receptor and subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells. **J. Steroid Biochem Mol Biol,** 2005. 94 (1-3): 71-81.

Maillard S, Ameller T, Gauduchon J, **Gougelet** A, *et al.* Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. **J Steroid Biochem Mol Biol.** 2005 Feb; 94(1-3): 111-21.

Marsaud V., **Gougelet A**., Maillard S. and Renoir J.M. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ER), differentially affect ER extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. **Mol Endocrinol,** 2003. 17: 2013-27.

International reviews

J. Sanceau and **Gougelet A.** Epigenetic mechanisms of liver tumor resistance to immunotherapy. **World *J Hepatol.*** (Submitted).

Gougelet A, Colnot S. Une Imagerie métabolique des cancers primitifs du foie basée sur leur addiction à la Choline permet de prédire leur oncogénotype, et de proposer une piste thérapeutique. **Med Sci (Paris).** 2020 Apr;36(4):322-326. doi: 10.1051/medsci/2020051.

A. Gougelet and C. Desbois-Mouthon. Non-coding RNAs Open a New Chapter in Liver Cancer Treatment. ***Clin Res Hepatol Gastroenterol.*** 2019, 43 (6): 630-637. 10.1016/j.clinre.2019.07.005

A. Gougelet. Epigenetic modulation of immunity: towards new therapeutic avenues in hepatocellular carcinoma? **Gut**. 2019; 68 (10): 1727-1728. doi: 10.1136/gutjnl-2019-319084.

A. Gougelet. Exosomal microRNAs as a potential therapeutic strategy in hepatocellular carcinoma. **World *J Hepatol.*** 2018; 10(11): 785-789. doi : 10.4254/wjh.v10.i11.785.

Lechel A and **Gougelet A.** Early HCC treatment: a future strategy against interferon/miR-484 axis to revert precancerous lesions? **Gut.** 2016 Mar 4. 65: (7) 1073-1074. doi: 10.1136/gutjnl-2016-311446.

Gougelet A, Colnot S. Hepatocellular carcinoma diagnosis: Circulating microRNAs emerge as robust biomarkers. **Clin Res Hepatol Gastroenterol.** 2016 Sep; 40(4): 367-9. doi: 10.1016/j.clinre.2015.12.010.

Gougelet A, Colnot S. Les microARN dans le cancer du foie: à l'orée de nouvelles thérapies ciblées? **Med Sci (Paris).** 2013 Oct; 29(10): 861-7. doi: 10.1051/medsci/20132910013.

Gougelet A, Colnot S. MicroRNA-feedback loop as a key modulator of liver tumorigenesis and inflammation.**World J Gastroenterol.** 2013 Jan 28; 19(4): 440-4. doi: 10.3748/wjg.v19.i4.440.

Gougelet A, Colnot S. A Complex Interplay between Wnt/β-Catenin Signalling and the Cell Cycle in the Adult Liver. **Int J Hepatol.** 2012; 2012:816125. doi: 10.1155/2012/816125.

Gougelet A., Mansuy A. et J-Y Blay. De l'eau au moulin de thérapies ciblant l'interleukine-6 dans les tumeurs épithéliales. **Med&Sciences,** 2008 Aug-Sep; 24(8-9): 694-6.

Book chapter

Gougelet A, Colnot S. Chapter 8: MicroRNAs linking cancer and inflammation: focus on liver cancer in the book "MicroRNAs: Key Regulators of Oncogenesis", Springer.

J. Sanceau and **Gougelet A.** Applications of Non-Coding RNAs in Liver Cancer Patients in the book "Clinical Applications of Non-Coding RNAs in Cancer" from Elsevier. (Submitted).